MELANIE COKER: Open Payments
NPI 1376609990 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,091 in 47 payments from 11 companies in 2025. Trend: 2023 $856 · 2024 $1,113 · 2025 $1,091
Food & beverage: $1,091
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 9 | $230 |
| GlaxoSmithKline, LLC. | 10 | $186 |
| Eisai Inc. | 4 | $183 |
| Genmab U.S., Inc. | 5 | $124 |
| ABBVIE INC. | 5 | $93 |
| AstraZeneca Pharmaceuticals LP | 4 | $68 |
| Caris MPI, Inc. | 3 | $55 |
| VERTEX PHARMACEUTICALS INCORPORATED | 3 | $54 |
| Astellas Pharma US Inc | 2 | $42 |
| Myriad Genetic Laboratories, Inc. | 1 | $33 |
Products named: JEMPERLI, Lenvima, LYNPARZA, KEYTRUDA, ELAHERE, Tivdak, MI CANCER SEEK, JOURNAVX.
Industry payments across MS — which companies pay providers there.
